Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019027034) NOVEL POLYPEPTIDE AND APPLICATION THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/027034 International Application No.: PCT/JP2018/029183
Publication Date: 07.02.2019 International Filing Date: 03.08.2018
IPC:
C07K 14/705 (2006.01) ,A61K 38/10 (2006.01) ,A61P 1/00 (2006.01) ,A61P 9/14 (2006.01) ,A61P 11/00 (2006.01) ,A61P 17/00 (2006.01) ,A61P 43/00 (2006.01) ,C07K 7/08 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
10
Peptides having 12 to 20 amino acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1
Drugs for disorders of the alimentary tract or the digestive system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
14
Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17
Drugs for dermatological disorders
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
7
Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04
Linear peptides containing only normal peptide links
08
having 12 to 20 amino acids
Applicants:
公立大学法人福島県立医科大学 FUKUSHIMA MEDICAL UNIVERSITY [JP/JP]; 福島県福島市光が丘一番地 1, Hikarigaoka, Fukushima-shi, Fukushima 9601295, JP
Inventors:
池添 隆之 IKEZOE Takayuki; JP
本田 剛一 HONDA Goichi; JP
Agent:
特許業務法人特許事務所サイクス SIKS & CO.; 東京都中央区京橋一丁目8番7号 京橋日殖ビル8階 8th Floor, Kyobashi-Nisshoku Bldg., 8-7, Kyobashi 1-chome, Chuo-ku, Tokyo 1040031, JP
Priority Data:
2017-15129004.08.2017JP
Title (EN) NOVEL POLYPEPTIDE AND APPLICATION THEREOF
(FR) NOUVEAU POLYPEPTIDE ET SON APPLICATION
(JA) 新規ポリペプチド及びその用途
Abstract:
(EN) The following peptide or salts thereof have a strong cytoprotective effect and a sufficiently reduced blood-coagulating effect: X1CPEGYILDDGX2ICTDIDE (cysteine residues (C) second and fourteenth from the N end form an S-S bond to bond together; the S-S bond may be substituted by a group represented by CHR1-CHR2 (R1 and R2 each indicate a hydrogen atom, a C1-4 alkyl group, a halogen atom, a hydroxyl group, or an amino group); X1 is not present, or indicates a glutamic acid residue (E) or an aspartic acid residue (D); X2 indicates a phenylalanine residue, an alanine residue, or a tyrosine residue).
(FR) La présente invention concerne un peptide ou des sels de celui-ci présentant un fort effet cytoprotecteur et un effet de coagulation sanguine suffisamment réduit : X1CPEGYILDDGX2ICTDIDE (deuxième résidus (C) de cystéine et quatorzième à partir de l'extrémité N forment une liaison S-S pour se lier ensemble ; la liaison S-S peut être substituée par un groupe représenté par CHR1-CHR2 (R1 et R2 représentent chacun un atome d'hydrogène, un groupe alkyle en C1-4, un atome d'halogène, un groupe hydroxyle ou un groupe amino) ; X1 n'est pas présent, ou indique un résidu d'acide glutamique (E) ou un résidu d'acide aspartique (D) ; X2 représente un résidu phénylalanine, un résidu alanine ou un résidu tyrosine).
(JA) 強い細胞保護作用を有し、かつ血液抗凝固作用が十分に軽減された下記ポリペプチド又はその塩:XCPEGYILDDGXICTDIDE(N末端から2番目及び14番目のシステイン残基(C)はS-S結合を形成して互いに結合しており、該S-S結合はCHR-CHR(R及びRは水素原子、炭素数1~4のアルキル基、ハロゲン原子、水酸基、又はアミノ基を示す)で表される基で置き換えられていてもよく;Xは存在しないか、又はグルタミン酸残基(E)若しくはアスパラギン酸残基(D)を示し;Xはフェニルアラニン残基、アラニン残基、又はチロシン残基を示す)
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)